Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Exp Neurol. 2015 Aug 13;273:151–160. doi: 10.1016/j.expneurol.2015.08.008

Figure 1.

Figure 1

Combination therapy with lenalidomide and nanoceria ameliorates symptoms in the EAE MS mouse model. A. Study design. B. Clinical scores. (Len, lenalidomide; NC, nanoceria; Len+NC, lenalidomide + nanoceria). **p<0.01 compared to Vehicle, Len and NC groups. Two-way ANOVA. C. Fraction of mice that developed a maximum clinical score greater than 1. **p<0.01 compared to Vehicle, Len and NC groups. Chi-square test. D. Rotarod motor performance data from evaluations made on EAE days 7 and 17. *p<0.05 compared to Vehicle, Len and NC groups. ANOVA with Bonferroni post-hoc test. E. Animal body weights over the course of the experiment. *p<0.05; **p<0.01. ANOVA with Bonferroni post-hoc test.